Livforsakringsbolaget Skandia, Omsesidigt Alnylam Pharmaceuticals, Inc. Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $1.72 Billion
- Q3 2024
A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 1,000 shares of ALNY stock, worth $286,910. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,000
Previous 200
400.0%
Holding current value
$286,910
Previous $48,000
472.92%
% of portfolio
0.02%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ALNY
# of Institutions
635Shares Held
108MCall Options Held
2.33MPut Options Held
2.15M-
Capital World Investors Los Angeles, CA15MShares$4.3 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.59 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.74 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.78 Billion0.28% of portfolio
-
Baillie Gifford & CO6.03MShares$1.73 Billion1.16% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $35.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...